Etest is a new concept for MIC determinations for antimicrobial agents that is based on a predefined antibiotic gradient on a plastic strip calibrated with a continuous logarithmic MIC Susceptibility testing. Etest strips were obtained from AB Biodisk. For agar dilution, antibiotic compounds were obtained from the following sources: amikacin (Bristol-Myers Squibb), ceftazidime (Glaxo), ciprofloxacin (Bayer), clarithromycin (Abbott), doxycycline (Pfizer), fusidic acid (Lovens), imipenem (MSD), rifampin (CIBA-GEIGY), and trimethoprim (Wellcome). Stock solutions were prepared according to the instructions of the manufacturers and were kept at -70°C if not used immediately. Plates containing antibiotics were prepared by incorporating twofold serial dilutions of each antibiotic in PDM ASM II agar, a semidefined medium for susceptibility testing (AB Biodisk).
Mycobacterium chelonae and M. fortuitum are clinically important species of rapidly growing mycobacteria which form visible colonies on solid media within 3 to 7 days. Pulmonary, skin, soft tissue, and other types of infections caused by these mycobacteria are often difficult to treat because of widespread resistance to antibacterial agents, including a majority of specific antituberculosis drugs. Nevertheless, conventional antituberculosis therapy has often been used for the treatment of such infections. Increased understanding of drug resistance and reliable in vitro susceptibility data, including the synergistic potential of drug combinations, will contribute to an adequate selection of drug therapy for these infections. Thus, there is a need for accurate and rapid methods for in vitro susceptibility testing of clinically relevant rapidly growing mycobacteria.
Etest (AB Biodisk, Solna, Sweden) is a new concept for MIC determinations for antimicrobial agents. It has been shown to compare well with conventional dilution techniques (1, 2, 7) and has proved to be useful in reference work on antibiotics (10) . In the present study on rapidly growing mycobacteria, we compared this newly developed MIC technique with a reference agar dilution method. The MICs of amikacin, ceftazidime, ciprofloxacin, clarithromycin, doxycycline, erythromycin, fusidic acid, imipenem, rifampin, and trimethoprim were initially determined for Susceptibility testing. Etest strips were obtained from AB Biodisk. For agar dilution, antibiotic compounds were obtained from the following sources: amikacin (Bristol-Myers Squibb), ceftazidime (Glaxo), ciprofloxacin (Bayer), clarithromycin (Abbott), doxycycline (Pfizer), fusidic acid (Lovens), imipenem (MSD), rifampin (CIBA-GEIGY), and trimethoprim (Wellcome). Stock solutions were prepared according to the instructions of the manufacturers and were kept at -70°C if not used immediately. Plates containing antibiotics were prepared by incorporating twofold serial dilutions of each antibiotic in PDM ASM II agar, a semidefined medium for susceptibility testing (AB Biodisk).
Colonies from a Lowenstein-Jensen tube were homogenized in phosphate-buffered saline (pH 7.0) to achieve turbidity equal to a McFarland 1.0 standard, corresponding to approximately 109 CFU/ml. This bacterial suspension was used both for agar dilution by inoculating plates with a Steers replicator and for Etest by swabbing the inoculum on the surface of a 140-mm agar plate. The MIC was read as the lowest concentration allowing no visible growth after 3 days.
Etest was used according to the manufacturer's instructions. Strips were applied to inoculated agar plates (depth, 4 ± 0.5 mm), which were then incubated in 5% CO2 at 37°C. The MIC (end point) was read after 72 h from the scale on the strip at the point at which heavy growth was inhibited, but trailing growth or occasional colonies in the inhibition zone were noted. Different inoculation techniques, such as flooding, swabbing, and spreading the inoculum with sterile beads, were investigated. The effects of preincubation of the microorganisms and prediffusion of the antibiotics were studied to determine the critical times for zone edge formation for M. fortuitum and M. chelonae in relation to the stability of the antibiotic gradient.
RESULTS
The two most active antibiotics were amikacin, which inhibited all M. fortuitum and M. chelonae strains at 0.032 to 1 mg/liter, and ciprofloxacin, which inhibited M. fortuitum at 0.006 to 0.047 mg/liter and M. chelonae at 0.032, 0.047, and Table 2 . There was a wide range of activity for many of the drugs. Isolates of M. chelonae were generally more resistant than those of M. fortuitum.
The effect of preincubation of strains prior to drug exposure was studied to determine the critical time for zone edge demarcation for these mycobacteria. Agar plates inoculated with representative strains of M. fortuitum and M. chelonae were preincubated at 37°C, and amikacin Etest strips were applied at various intervals between 0 and 12 h. The width of the inhibition ellipse decreased with increasing preincubation, but the MIC intersection remained constant. A lawn of confluent growth with no inhibition ellipse was seen after approximately 6 h of preincubation. In experiments with various intervals of prediffusion of the antibiotic between 0 and 8 h prior to incubation, the width of the ellipse increased with increasing prediffusion, but the MIC intersection remained the same.
DISCUSSION
Currently there are no generally accepted drug regimens for infections caused by M. fortuitum and M. chelonae. There is a large variation in antibiotic resistance patterns among such strains, with M. chelonae being normally more resistant than M. fortuitum. In vitro susceptibility data are important for therapy guidance for individual patients and for documenting resistance patterns and resistance mechanisms for this group of bacteria. Different approaches for in vitro susceptibility testing of rapidly growing mycobacteria include agar dilution (12, 14, 15) , agar disk elution (11) , disk diffusion (3, 14) , broth microdilution (12, 13), and a tablet diffusion method (4) . To grow. This also was the time at which the demarcation of the zone edge was formed.
The inability of some strains to yield visible colonies within 3 days of incubation was a problem that could be expected, since the definition of rapid growth in mycobacteriology is growth on solid medium within 7 days. Thus, the susceptibility patterns for a number of clinical isolates could not be determined with Etest; this was true more frequently for M. chelonae (including reference strain ATCC 19977) than for M. fortuitum. In attempts to reduce this problem, we tested the following variables: preincubation of bacteria in broth before inoculation of agar plates, different agar media and supplements, Lowenstein-Jensen egg medium, incubation in a 5% CO, atmosphere, and a reduced incubation temperature.
None of these approaches significantly increased the rate of growth of the strains not growing within 3 days, whereas enhanced growth of some strains that had already produced visible colonies within this time was noted occasionally. An egg-based culture medium supported the growth of a larger number of mycobacterial strains than did PDM ASM II agar with oleic acid-albumin-dextrose catalase but had the drawback of yielding less clear inhibition zones, making reading of end points difficult. Also, the MICs of rifampin were much higher on this medium, indicating an interaction between rifampin and components of the medium. To be able to use Etest for MIC determinations of all strains of M. fortuitum and M. chelonae, further improvements in growth conditions need to be established or the possibility of using longer incubation periods needs to be evaluated.
Etest can also be used for investigations of drug combinations. Studies on antibacterial effects of combined drugs have been valuable in susceptibility testing of mycobacteria, such as M. avium complex and M. malmoense (5, 6) . Preliminary results indicated that the inhibitory effects of rifampin, fusidic acid, and imipenem against M. fortuitum were potentiated when these drugs were combined with ethambutol. Further studies on the antibacterial effects of drug combinations against M. chelonae and M. fortuitum should be conducted. Etest seems to be a suitable method for such investigations. Additional work is needed to establish the clinical significance of the MICs of individual drugs and drug combinations against rapidly growing mycobacteria. This work would be best done in multicenter trials in which clinical responses can be correlated with in vitro susceptibility data.
